HRS-9231

This is an open-label, non-randomized, parallel cohorts design, multicenter, single dose phase I study.
The primary objectives are:
To evaluate the pharmacokinetics (plasma and urine) profile of HRS-9231 following single intravenous injection (0.05 mmol/kg body weight) in patients with mild to severe renal impairment and in healthy volunteers with normal renal function used as reference.
To assess dialysability of HRS-923 following a single intravenous injection (0.05 mmol/kg body weight) in patients with end stage renal disease requiring hemodialysis.

1、评价在健康受试者中静脉给予HRS-9231注射液的安全性和耐受性。 2、评价在健康受试者中静脉给予HRS-9231注射液的药代动力学（PK）和药效动力学（PD）特征。 3、 评价在健康受试者中静脉给予HRS-9231注射液对QTc间期的影响。